CY1124388T1 - Εμβολιο για ανοσοεξασθενημενους δεκτες - Google Patents

Εμβολιο για ανοσοεξασθενημενους δεκτες

Info

Publication number
CY1124388T1
CY1124388T1 CY20211100298T CY211100298T CY1124388T1 CY 1124388 T1 CY1124388 T1 CY 1124388T1 CY 20211100298 T CY20211100298 T CY 20211100298T CY 211100298 T CY211100298 T CY 211100298T CY 1124388 T1 CY1124388 T1 CY 1124388T1
Authority
CY
Cyprus
Prior art keywords
peptides
vaccine
nucleic acids
immune compromised
recipients
Prior art date
Application number
CY20211100298T
Other languages
English (en)
Inventor
Paula Maria Das Neves Ferreira Da Silva
Pedro Jorge Fonseca Madureira
Original Assignee
Universidade Do Porto - Reitoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14398006.8A external-priority patent/EP2955194A1/en
Application filed by Universidade Do Porto - Reitoria filed Critical Universidade Do Porto - Reitoria
Publication of CY1124388T1 publication Critical patent/CY1124388T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01012—Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) (1.2.1.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01022—Lactaldehyde dehydrogenase (1.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Η εφεύρεση παρέχει πεπτίδια προερχόμενα από διαδεδομένη πρωτεΐνη, και νουκλεϊκά οξέα κωδικεύοντα τέτοια πεπτίδια. Η εφεύρεση εκτείνεται σε διάφορες χρήσεις αυτών των πεπτιδίων και νουκλεϊκων οξέων, για παράδειγμα, ως αντιγόνα για χρήση σε εμβόλια αυτά καθ' αυτά και στη δημιουργία αντισωμάτων για χρήση σε θεραπευτικές φαρμακευτικές ουσίες για την πρόληψη, βελτίωση ή αγωγή μολύνσεων προκαλούμενων από σηψογόνα βακτήρια. Η εφεύρεση ωφελεί ιδίως ανοσοεξασθενημένους δέκτες όπως νεογνά, βρέφη, παιδιά, γυναίκες γόνιμης ηλικίας, εγκύους γυναίκες, έμβρυα, και ηλικιωμένους και διαβητικούς.
CY20211100298T 2014-06-12 2021-04-07 Εμβολιο για ανοσοεξασθενημενους δεκτες CY1124388T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14398006.8A EP2955194A1 (en) 2014-06-12 2014-06-12 Neonatal vaccine
EP15398003 2015-03-30
PCT/EP2015/063243 WO2015189422A1 (en) 2014-06-12 2015-06-12 Vaccine for immunocompromised hosts

Publications (1)

Publication Number Publication Date
CY1124388T1 true CY1124388T1 (el) 2022-07-22

Family

ID=53385660

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100298T CY1124388T1 (el) 2014-06-12 2021-04-07 Εμβολιο για ανοσοεξασθενημενους δεκτες

Country Status (17)

Country Link
US (2) US11066652B2 (el)
EP (1) EP3155004B1 (el)
JP (2) JP6813480B2 (el)
KR (2) KR20170018920A (el)
CN (1) CN106795502B (el)
CA (1) CA2969878C (el)
CY (1) CY1124388T1 (el)
DK (1) DK3155004T3 (el)
ES (1) ES2862534T3 (el)
HR (1) HRP20210458T1 (el)
HU (1) HUE053668T2 (el)
LT (1) LT3155004T (el)
MA (1) MA39957B1 (el)
PL (1) PL3155004T3 (el)
RS (1) RS61549B1 (el)
SI (1) SI3155004T1 (el)
WO (1) WO2015189422A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795502B (zh) 2014-06-12 2021-12-14 波尔图大学 用于免疫受损宿主的疫苗
US11718648B2 (en) 2017-01-05 2023-08-08 Evaxion Biotech A/S Vaccines targeting Pseudomonas aeruginosa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532894A (en) * 1998-04-29 2005-10-28 Univ Southern California Retroviral vectors including modified envelope escort proteins
JP2008529504A (ja) * 2005-02-08 2008-08-07 ニューヨーク ブラッド センター 重症急性呼吸器症候群関連コロナウイルスに対する中和モノクローナル抗体
WO2007132461A2 (en) * 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
ES2298055A1 (es) * 2006-08-09 2008-05-01 Fundacion Marques De Valdecilla Peptidos inmunogenicos frente a los generos listeria y mycobacterium, anticuerpos y usos de los mismos.
US20120100172A1 (en) * 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
JP2013503158A (ja) * 2009-08-26 2013-01-31 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ 炎症性サイトカインカスケードによって媒介される病態を、ｇａｐｄｈ阻害剤を用いて治療する方法
WO2011067758A2 (en) * 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CN106795502B (zh) 2014-06-12 2021-12-14 波尔图大学 用于免疫受损宿主的疫苗

Also Published As

Publication number Publication date
CN106795502A (zh) 2017-05-31
US11066652B2 (en) 2021-07-20
PL3155004T3 (pl) 2021-10-25
MA39957B1 (fr) 2021-04-30
ES2862534T3 (es) 2021-10-07
EP3155004A1 (en) 2017-04-19
DK3155004T3 (da) 2021-04-06
KR20170018920A (ko) 2017-02-20
US20220049229A1 (en) 2022-02-17
RS61549B1 (sr) 2021-04-29
CA2969878C (en) 2021-05-04
LT3155004T (lt) 2021-03-25
KR20200013809A (ko) 2020-02-07
CA2969878A1 (en) 2015-12-17
CN106795502B (zh) 2021-12-14
EP3155004B1 (en) 2021-01-13
MA39957A (fr) 2017-04-19
US20170191040A1 (en) 2017-07-06
JP2017518769A (ja) 2017-07-13
US11834684B2 (en) 2023-12-05
WO2015189422A1 (en) 2015-12-17
HUE053668T2 (hu) 2021-07-28
HRP20210458T1 (hr) 2021-05-14
JP2021000134A (ja) 2021-01-07
SI3155004T1 (sl) 2021-08-31
JP6813480B2 (ja) 2021-01-13

Similar Documents

Publication Publication Date Title
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
JOP20200091A1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
BR112017003108A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
CY1122705T1 (el) Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας,και μεθοδοι χρησης τους
BR112013012555A2 (pt) peptídeos imunogênicos para o uso na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunes a alofatores, doenças alérgicas, tumores, rejeição a enxertos e respostas imunes contra vetores virais usados para a terapia de genes ou na vacinação de genes
EA201690504A1 (ru) Антигенсвязывающие белки к gitr
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
CY1124388T1 (el) Εμβολιο για ανοσοεξασθενημενους δεκτες
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
EA201790296A1 (ru) Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9
MX363149B (es) Vacunas de nucleoproteina de la influenza.
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
NZ730708A (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
EA201990719A1 (ru) Новые промоторы
UY36990A (es) Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
WO2015171505A3 (en) Antigens of pneumocystis murina and uses thereof